Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera

類似資料

• Chronic Leg Ulceration Associated with Polycythemia Vera Responding to Ruxolitinib (Jakafi(®))
  著者:: Shanmugam, Victoria K., 等
  出版事項: (2013)
• Ruxolitinib for the Treatment of Patients With Polycythemia Vera
  著者:: Kiladjian, Jean-Jacques, 等
  出版事項: (2015)
• Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple Myeloma and for First-Line Treatment of Patients with Mantle-Cell Lymphoma
  著者:: Raedler, Lisa
  出版事項: (2015)
• Zydelig (Idelalisib): First-in-Class PI3 Kinase Inhibitor Approved for the Treatment of 3 Hematologic Malignancies
  著者:: Raedler, Lisa A.
  出版事項: (2015)
• Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting
  著者:: Raedler, Lisa A.
  出版事項: (2015)